Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study.

ABSTRACT:

Introduction

Non-vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy to prevent ischaemic stroke in patients with atrial fibrillation (AF). However, studies on the effectiveness and safety of edoxaban for Chinese patients with AF, are limited.

Methods

We report the 1-year interim follow-up data on edoxaban use in Chinese patients with AF from the ETNA-AF-China (NCT04747496), a multicentre, prospective, observational study conducted in 89 centres across the Chinese Mainland, enrolling 5,001 patients with a total of 2-year follow-up. No adjustment for multiple testing was made; therefore, all P values must be interpreted in an exploratory or descriptive manner.

Results

Overall, 4,877 patients (60 mg edoxaban: 54.3%; 30 mg edoxaban: 45.7%)

SUBMITTER: Guo X 

PROVIDER: S-EPMC12872560 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature